Premium
Metformin attenuates angiotensin II‐induced TGFβ1 expression by targeting hepatocyte nuclear factor‐4‐α
Author(s) -
Chen Ruifei,
Feng Yenan,
Wu Jimin,
Song Yao,
Li Hao,
Shen Qiang,
Li Dan,
Zhang Jianshu,
Lu Zhizhen,
Xiao Han,
Zhang Youyi
Publication year - 2018
Publication title -
british journal of pharmacology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13753
Subject(s) - angiotensin ii , ampk , cardiac fibrosis , metformin , amp activated protein kinase , transforming growth factor , endocrinology , medicine , fibrosis , chemistry , protein kinase a , kinase , receptor , biochemistry , diabetes mellitus
Metformin, a small molecule, antihyperglycaemic agent, is a well-known activator of AMP-activated protein kinase (AMPK) and protects against cardiac fibrosis. However, the underlying mechanisms remain elusive. TGFβ1 is a key cytokine mediating cardiac fibrosis. Here, we investigated the effects of metformin on TGFβ1 production induced by angiotensin II (AngII) and the underlying mechanisms.